Researchers at Washington University School of Medicine have reported that gantenerumab, an experimental drug aimed at Alzheimer's disease, could potentially delay symptoms in genetically predisposed individuals. In a study involving 73 participants with Dominantly Inherited Alzheimer’s Disease (DIAD), those receiving the drug for an extended period—averaging eight years—showed up to a 50% reduction in cognitive decline risk. The findings suggest that early intervention might be crucial for effective treatment. While encouraging, the study noted significant limitations, including a small sample size and issues related to treatment discontinuation due to drug support withdrawal. Although initial results are promising, the necessity for larger, long-term studies to confirm efficacy was emphasized. Gantenerumab targets beta-amyloid protein plaques associated with Alzheimer's progression, and although previously failing larger trials, this recent research highlights the potential of preventive strategies in Alzheimer's treatment.

Source 🔗